PDF(Pubmed)
Abstract：
The development of a new cholangioscope, the SpyGlass™ Discover (Boston Scientific), has allowed the laparoscopic transcystic common bile duct exploration and stone clearance. The possibility of simultaneous treatment of choledocholithiasis during early laparoscopic cholecystectomy offers the opportunity to enormously reduce the time between acute cholecystitis diagnosis and the execution of cholecystectomy with better outcomes for patients. Furthermore, an altered anatomy of the gastrointestinal tract is not an obstacle to this technique. The aim of the study was to determine whether this new procedure is feasible, safe, and effective.
The investigation employs a retrospective case series study including all consecutive patients with a diagnosis of common bile duct stones undergoing cholecystectomy and intraoperative laparoscopic common bile duct clearance using SpyGlass™ Discover at IRCCS Policlinico San Matteo in Pavia (Italy). Eighteen patients were included from May 2022 to May 2023.
A complete clearance of the common bile duct was obtained in 88.9% of patients. The mean postoperative length of stay was 3 days. No major complications occurred. After a median follow-up of 8 months, no recurrence of biliary events or readmissions occurred.
This procedure has proven to be feasible, safe, and effective.
The investigation employs a retrospective case series study including all consecutive patients with a diagnosis of common bile duct stones undergoing cholecystectomy and intraoperative laparoscopic common bile duct clearance using SpyGlass™ Discover at IRCCS Policlinico San Matteo in Pavia (Italy). Eighteen patients were included from May 2022 to May 2023.
A complete clearance of the common bile duct was obtained in 88.9% of patients. The mean postoperative length of stay was 3 days. No major complications occurred. After a median follow-up of 8 months, no recurrence of biliary events or readmissions occurred.
This procedure has proven to be feasible, safe, and effective.
摘要：
目的：新型胆道镜的研制，SpyGlass™发现（波士顿科学），允许腹腔镜下胆总管探查和结石清除。在早期腹腔镜胆囊切除术中同时治疗胆总管结石的可能性提供了机会，可以极大地减少诊断急性胆囊炎和执行胆囊切除术之间的时间，从而为患者带来更好的预后。此外，胃肠道解剖结构的改变并不是这项技术的障碍。这项研究的目的是确定这种新程序是否可行，安全,而且有效。
方法：本研究采用回顾性病例系列研究，包括所有连续诊断为胆总管结石的患者，在意大利帕维亚的IRCCSPoliclinicoSanMatteo使用SpyGlass™Discover行胆囊切除术和术中腹腔镜胆总管清除术。从2022年5月至2023年5月，包括18名患者。
结果：88.9%的患者获得了胆总管的完全清除。术后平均住院时间为3天。无重大并发症发生。中位随访8个月后，无胆道事件复发或再入院.
结论：此程序已被证明是可行的，安全,而且有效。
方法：本研究采用回顾性病例系列研究，包括所有连续诊断为胆总管结石的患者，在意大利帕维亚的IRCCSPoliclinicoSanMatteo使用SpyGlass™Discover行胆囊切除术和术中腹腔镜胆总管清除术。从2022年5月至2023年5月，包括18名患者。
结果：88.9%的患者获得了胆总管的完全清除。术后平均住院时间为3天。无重大并发症发生。中位随访8个月后，无胆道事件复发或再入院.
结论：此程序已被证明是可行的，安全,而且有效。
